John Haluschak, MD
Medical Oncology · Oakwood, OHNPI 1407895535
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by AstraZeneca at 53.0% of the total. Reporting peaked in 2023 at $4,323 and has fallen 99.4% since, to $27 in 2025.
Across 126 payments — averaging $71.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Pfizer$983
- E.r. Squibb & Sons, L.L.C.$250
- Pharmacyclics LLC, An Abbvie Company$226
- AbbVie$207
- Novartis$201
- plus $2K from 31 others
Across 17 payments — averaging $4059.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Clovis Oncology, Inc.$50K
- AstraZeneca$11K
- Puma Biotechnology, Inc.$8K
What the payments were for
- Consulting fees$4,16347%
- Speaking & faculty fees$1,38816%
- Food & beverage$2,97333%
- Education$4235%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $4,741 |
| Pfizer | 4 | $983 |
| E.r. Squibb & Sons, L.L.C. | 6 | $250 |
| Pharmacyclics LLC, An Abbvie Company | 11 | $226 |
| AbbVie | 8 | $207 |
| Novartis | 6 | $201 |
| Amgen | 12 | $194 |
| GSK | 3 | $155 |
| Sanofi-aventis U.S. LLC | 2 | $155 |
| Johnson & Johnson | 4 | $153 |
| Rigel Pharmaceuticals, Inc. | 3 | $152 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $145 |
| Merck | 8 | $144 |
| Blueprint Medicines Corporation | 4 | $140 |
| CTI Biopharma Corp. | 1 | $139 |
| Incyte Corporation | 1 | $125 |
| Agios Pharmaceuticals, Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 5 | $110 |
| Bayer | 4 | $73 |
| Gilead(2 entities) | 4 | $59 |
| Sanofi | 3 | $55 |
| Dendreon Pharmaceuticals LLC | 2 | $52 |
| Array Biopharma Inc | 2 | $46 |
| Mirati Therapeutics, Inc. | 2 | $39 |
| Genentech USA, Inc. | 3 | $37 |
| AVEO Pharmaceuticals, Inc. | 2 | $35 |
| Bristol Myers Squibb | 2 | $30 |
| Lilly USA, LLC | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Foundation Medicine, Inc. | 1 | $16 |
| Spectrum Pharmaceuticals Inc. | 1 | $16 |
| Taiho Oncology, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| G1 Therapeutics, Inc. | 1 | $14 |
| Pharmacosmos Therapeutics Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,947 in reported general payments places this provider in the 70th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 27 | $119,141 |
| EliquisApixaban | 166 | $113,130 |
| Dexamethasone | 33 | $564 |
| Olanzapine | 17 | $371 |
| Acyclovir | 11 | $285 |
| Prednisone | 59 | $253 |
| Hydroxyurea | 17 | $203 |
| Letrozole | 12 | $186 |
| Omeprazole | 14 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $983 | $113,130166 claims |
| Lilly USA, LLCOlanzapine | $25 | $37117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 157 medical oncology providers in Ohio.
Other medical oncology in Oakwood
- David CarboneColumbus$438K
- Elyse LowerCincinnati$312K
- Moshe OrnsteinCleveland$249K
- Christian RolfoColumbus$227K
- Timothy MooreColumbus$213K
- Maryam LustbergColumbus$176K
- Suneel KamathCleveland$120K
- Mark MarinellaKettering$84K
- Timothy BurnsColumbus$64K
- William TseCleveland$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.